Breaking News Instant updates and real-time market news.

HON

Honeywell

$115.61

0.35 (0.30%)

, GPS

Gap

$22.78

0.25 (1.11%)

08:59
10/07/16
10/07
08:59
10/07/16
08:59

On The Fly: Pre-market Movers

HIGHER: Gap (GPS), up 6.7% after it reported better than feared September same-store sales results... CIT Group (CIT), up 3.9% after it agreed to sell CIT Commercial Air to Avolon Holdings for $10B... Incyte (INCY), up 3% after updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat in combination with pembrolizumab, Merck's (MRK) anti-PD-1 therapy, were published as a poster at the European Society for Medical Oncology, or ESMO, Annual Congress... GW Pharmaceuticals (GWPH), up 3% after the stock was initiated with a Buy rating at Goldman Sachs. LOWER: Honeywell (HON), down 6% after the company lowered its guidance and announced restructuring plans... Ruby Tuesday (RT), down 5% after reporting quarterly results and stating that it is no longer providing guidance so that it can focus on long-term objectives amid plans to accelerate the execution of its Fresh Start Initiatives under new leadership to "better address the challenges currently facing the business"... Clovis Oncology (CLVS), up 20% after the company presented efficacy and safety data from its NDA dataset for rucaparib at the ESMO Congress... Merrimack Pharmaceuticals (MACK), down 3.7% after the stock was downgraded to Neutral from Overweight by JPMorgan analyst Anupam Rama, who said that key pipeline catalysts aren't likely until Q2 of 2017 and beyond... SolarEdge (SEDG), down 5.6% after Goldman Sachs analyst Brian Lee downgraded the stock to Sell from Neutral, as he believes there will be increased challenges to SolarEdge's growth due to a reversal in market share gains and intensifying pricing pressure... OPKO Health (OPK), down 6.4% after Jefferies analyst Brandon Couillard said he views a no-coverage decision yesterday from Palmetto, a Medicare administrative contractor, for OPKO's 4Kscore prostate cancer test as a "major setback" for the company... Acacia Communications (ACIA), down 7% after the company's 4.5M share secondary offering priced at $100 per share... Tyson Foods (TSN), down 4% after the stock was downgraded to Sell from Hold at Pivotal Research.

HON

Honeywell

$115.61

0.35 (0.30%)

GPS

Gap

$22.78

0.25 (1.11%)

CIT

CIT Group

$36.40

0.14 (0.39%)

ACIA

Acacia Communications

$109.42

-4.12 (-3.63%)

GWPH

GW Pharmaceuticals

$133.10

-0.35 (-0.26%)

MACK

Merrimack

$5.98

0.02 (0.34%)

SEDG

SolarEdge

$17.22

0.04 (0.23%)

CLVS

Clovis

$35.77

-1.51 (-4.05%)

INCY

Incyte

$94.78

-0.91 (-0.95%)

MRK

Merck

$62.66

-0.14 (-0.22%)

OPK

OPKO Health

$10.43

-0.31 (-2.89%)

RT

Ruby Tuesday

$2.51

0.04 (1.62%)

TSN

Tyson Foods

$74.38

0.61 (0.83%)

  • 07

    Oct

  • 07

    Oct

  • 12

    Oct

  • 21

    Oct

  • 25

    Oct

  • 06

    Nov

  • 14

    Nov

  • 23

    Feb

  • 07

    Oct

HON Honeywell
$115.61

0.35 (0.30%)

10/06/16
BARD
10/06/16
INITIATION
Target $135
BARD
Outperform
Honeywell initiated with an Outperform at Baird
Baird analyst Peter.Arment initiated Honeywell with an Outperform and a $135 price target.
10/06/16
BARD
10/06/16
INITIATION
Target $135
BARD
Honeywell initiated with an Outperform at Baird
Baird analyst Peter.Arment initiated Honeywell with an Outperform and a $135 price target.
10/07/16
BERN
10/07/16
NO CHANGE
BERN
Honeywell still has positive attributes, says Bernstein
After Honeywell lowered its guidance and announced restructuring plans, Bernstein analyst Steven Winoker said that macro conditions and margins/restructuring led to the disappointing news. However, the analyst says that there are still multiple reasons to be upbeat on the stock, including his belief that the company's EPS growth will exceed 8% next year, and what he sees as the company's high margins and large cash reserves. The analyst keeps a $135 price target and Outperform rating on the stock.
10/07/16
JPMS
10/07/16
NO CHANGE
JPMS
Overweight
Honeywell selloff on guidance a buying opportunity, says JPMorgan
JPMorgan analyst C. Stephen Tusa recommends using the selloff in shares of Honeywell following the company's Q3 guidance cut as a buying opportunity. The analyst puts himself in the "not that bad in the grand scheme" camp and notes Honeywell has $25B in balance sheet capacity. Tusa has an Overweight rating on the shares.
GPS Gap
$22.78

0.25 (1.11%)

10/07/16
JEFF
10/07/16
NO CHANGE
Target $32
JEFF
Buy
Jefferies sees 'sizable upside potential' in Gap shares
Jefferies analyst Randal Konik raises his price target for Gap shares to $32 from $30 following the retailer's September results. Trends are Old Navy are accelerating while a bottom setting in at The Gap, Konik tells investors in a research note. The analyst sees an "asymmetric risk/reward" for shares with downside "fairly limited" and "sizable upside potential." He sees easy comparisons as a near-term catalyst and keeps a Buy rating on the shares.
10/07/16
UBSW
10/07/16
NO CHANGE
Target $16
UBSW
Sell
Gap distribution center fire impact not done being felt, says UBS
UBS analyst Michael Binetti noted Gap's distribution center fire in August had a significant impact on September sales and that the company estimates that the fire will be a 3 point drag to October same-store sales as well. Additionally, Binetti said Florida, Georgia and South Carolina account for 10% of the company's North America store count and that Gap will close some stores amid this weekend's hurricane, further impacting October sales. The company mentioned that merchant margins were higher than expected which should offset any negative earnings impact, however. The analyst is cautious of the company's ability to pull back on promotions to drive a comp inflection and reiterated his Sell rating and $16 price target on Gap shares.
08/19/16
MSCO
08/19/16
NO CHANGE
Target $21
MSCO
Underweight
Gap valuation stretched adn upside limited, says Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said Gap's valuation appears stretched and upside is limited. The analyst said even the most bullish expectations for $2.25-$2.30 in 2017 implies zero earnings growth since 2012, with less scope for cuts in marketing expense, wage inflation, and other SG&A inflation. Greenberger has an Underweight rating on Gap and a $21 price target on shares.
10/07/16
DBAB
10/07/16
UPGRADE
Target $24
DBAB
Hold
Gap upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Paul Trussell upgraded Gap to Hold saying the company's near- to medium-term setup is more favorable amid easing compares over the next few months and an improved apparel backdrop. Trussell raised his price target for the shares to $24 from $18.
CIT CIT Group
$36.40

0.14 (0.39%)

04/29/16
BOFA
04/29/16
DOWNGRADE
BOFA
Follow-up: CIT Group downgraded to Underperform at BofA/Merrill
As previously reported, BofA/Merrill downgraded CIT Group to Underperform from Buy. The firm's analyst said the restructuring to a complex franchise from a simplified bank may be extended until 2018 or longer, due to additional restructuring, a revised strategy, and a management overhaul. BofA/Merrill sees limited earnings visibility and believes sentiment will remain poor until the commercial air exit is complete and execution on the strategic plan shows progress.
04/29/16
BOFA
04/29/16
DOWNGRADE
BOFA
Underperform
CIT Group downgraded to Underperform from Buy at BofA/Merrill
10/07/16
STFL
10/07/16
DOWNGRADE
STFL
Hold
CIT Group downgraded at Stifel
As noted earlier, Stifel downgraded CIT to Hold from Buy. Analyst Christopher Brendler says that investors should sell into the rally that will result from the "impressive" price that the company received for its aircraft business and the approval of its capital plan by the Fed. The analyst says he is "skeptical" about the company's remaining business, while the company's planned share buyback will take time to materialize. Target to $41 from $40.
10/07/16
STFL
10/07/16
DOWNGRADE
STFL
Hold
CIT Group downgraded to Hold from Buy at Stifel
ACIA Acacia Communications
$109.42

-4.12 (-3.63%)

09/01/16
BOFA
09/01/16
NO CHANGE
Target $130
BOFA
Buy
Acacia Communications price target raised ot $130 from $88 at BofA/Merrill
BofA/Merrill analyst Tal Llani raised Acacia Communications' price target to $130 from $88 to reflect potential share gains and TAM expansion. The analyst remains constructive on shares despite recent strength given product superiority, sales growth, and potential upside to Street estimates. Llani rates Acacia a Buy.
09/09/16
DBAB
09/09/16
NO CHANGE
Target $125
DBAB
Buy
Acacia Communications price target raised to $125 from $90 at Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath raised his price target for Acacia Communications to $125 from $90 after joining the company's CEO and CFO in a non-deal roadshow. The analyst sees "little risk" to Q3 estimates given solid near-term order visibility in Datacenter Optical and China Metro build outs. The consensus view of Acacia's total addressable market at $4B is conservative and does not factor in up-sell into a $1B-$2B 100G Switching and Routing market, Bhagavath tells investors in a research note. He reiterates a Buy rating on the shares. Acacia closed yesterday down $2.31 to $117.89.
08/18/16
NEED
08/18/16
NO CHANGE
NEED
Nokia, Alcatel-Lucent win positive for optical component companies, says Needham
Needham analyst Alex Henderson says that Alcatel-Lucent (ALU)/Nokia (NOK) announcement of a major contract win to build over 30% share of China Mobile's (CHL) 2016-2017 new construction of optical network is also a major positive for optical component companies such as Oclaro (OCLR), NeoPhotonics (NPTN), Fabrinet (FN), Lumentum (LITE), Inphi (IPHI), and Acacia (ACIA). Henderson thinks this is likely the first of three major awards in China, which will likely result in the current sold-out conditions in the coherent optical market to stretch out well into 2017.
09/06/16
NEED
09/06/16
NO CHANGE
Target $20
NEED
Strong Buy
Needham remains a buyer of NeoPhotonics ahead of analyst day
Needham analyst Alex Henderson believes NeoPhotonics (NPTN) is "exceptionally well positioned" for strong results over the next 3-4 quarters. The analyst "aggressively recommends" investors Buy NeoPhotonics' shares before the company's analyst day on September 8. Further, Henderson thinks Acacia's (ACIA) over $4B market cap will likely drive them to be acquisitive, and notes that it may seek to reduce costs as a percent of revenues by a potential acquisition of, for example, NeoPhotonics or Oclaro (OCLR). He reiterates a Strong Buy rating and $20 price target on NeoPhotonics' shares.
GWPH GW Pharmaceuticals
$133.10

-0.35 (-0.26%)

09/26/16
CANT
09/26/16
NO CHANGE
Target $182
CANT
Buy
GW Pharmaceuticals price target raised to $182 from $165 at Cantor
10/04/16
LEER
10/04/16
INITIATION
Target $162
LEER
Outperform
GW Pharmaceuticals reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of GW Pharmaceuticals with an Outperform rating and $162 price target.
10/07/16
GSCO
10/07/16
INITIATION
Target $189
GSCO
Buy
GW Pharmaceuticals initiated with a Buy at Goldman
Goldman analyst Salveen Richter initiated GW Pharmaceuticals with a Buy saying he expects a solid launch trajectory for lead assets Epidiolex for Dravet Syndrome and Lennox-Gastaut Syndrome, two severe orphan epilepsies, and is modeling $1.6B in world-wide sales. Richter has a $189 price target on shares based on a blend of discounted cash flow for $161 per shares and M&A value of $349 per share.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
MACK Merrimack
$5.98

0.02 (0.34%)

10/07/16
JPMS
10/07/16
DOWNGRADE
Target $7
JPMS
Neutral
Merrimack downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Merrimack Pharmaceuticals to Neutral saying the shares are likely to be range-bound after rallying 36% from the 52-week low on September 20. Key pipeline catalysts aren't likely until Q2 of 2017 and beyond while 2016 estimates are not "meaningfully beatable," Rama tells investors in a research note. He lowered his price target for the shares to $7 from $8.
08/19/16
BTIG
08/19/16
INITIATION
BTIG
Neutral
Merrimack initiated with a Neutral at BTIG
BTIG analyst Ling Wang initiated Merrimack with a Neutral as he expects shares to be range-bound given the likely slow ramp-up of ONIVYDE and data from MM-302 and MM-121 won't be available until 2017 or beyond;
08/05/16
COWN
08/05/16
DOWNGRADE
COWN
Market Perform
Merrimack downgraded to Market Perform from Outperform at Cowen
08/05/16
BMUR
08/05/16
NO CHANGE
Target $13
BMUR
Buy
Merrimack price target lowered to $13 from $16 at Brean Capital
Brean Capital lowered its price target on Merrimack to $13 from $16 following Q2 results. The firm cited the sales miss on Onivyde, although they are encouraged by its early launch. Brean Capital reiterated its Buy rating on Merrimack shares.
SEDG SolarEdge
$17.22

0.04 (0.23%)

10/06/16
GSCO
10/06/16
DOWNGRADE
GSCO
Sell
SolarEdge downgraded to Sell from Neutral at Goldman
Goldman analyst Brian Lee downgraded SolarEdge to Sell from Neutral and lowered his price target to $13 from $19, with Lee saying he believes there will be increased challenges to SolarEdge's growth due to "a reversal in market share gains and intensifying pricing pressure."
10/06/16
GSCO
10/06/16
DOWNGRADE
GSCO
Sell
SolarEdge downgraded to Sell from Neutral at Goldman
09/08/16
09/08/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Underperform, $160 target at Cowen with analyst Jeffrey Osborne saying the company is well positioned for the long term but has a "material amount of execution risk" over the next 12 to 18 months. 2. AutoNation (AN) initiated with a Buy at CL King. 3. Wingstop (WING) initiated with an Overweight at KeyBanc. 4. Vivint Solar (VSLR), Sunrun (RUN), and SolarEdge (SEDG) initiated with an Outperform at JMP Securities with the firm initiated First Solar (FSLR) and SunPower (SPWR) with an Underperform. The firm also initiated Canadian Solar (CSIQ) with a Market Perform. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
ADAM
09/23/16
INITIATION
Target $27
ADAM
Buy
SolarEdge coverage assumed with a Buy at Canaccord
Target $27.
CLVS Clovis
$35.77

-1.51 (-4.05%)

09/21/16
JANY
09/21/16
DOWNGRADE
JANY
Neutral
Clovis downgraded to Neutral from Buy at Janney Capital
09/21/16
09/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Monsanto (MON) upgraded to Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the risk in the shares is "less than what the market assumes." 2. Barclays (BCS) upgraded to Buy from Hold at HSBC citing the pending disposal of non-core businesses and resulting value creation. 3. Etsy (ETSY) upgraded to Buy from Neutral at Monness Crespi with the firm's analyst believing that Etsy shares can still move higher and sees a solid opportunity for upward revisions from improving conversion rates due to enhanced search and mobile functionality, expanding take rates, and advanced cross-boarder commerce capabilities with vendors. 4. Clovis (CLVS) upgraded to Outperform from Neutral at Credit Suisse with analyst Kennen MacKay saying the potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition." 5. Jabil Circuit (JBL) upgraded to Buy from Neutral at UBS with analyst Steven Milunovich saying the company's cash flow is nearing an inflection amid an upturn in its Apple (AAPL) business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.
INCY Incyte
$94.78

-0.91 (-0.95%)

09/29/16
RAJA
09/29/16
UPGRADE
Target $115
RAJA
Outperform
Incyte upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Reni Benjamin upgraded Incyte to Outperform with a $115 price target following the release of an abstract showcasing "positive" long-term follow-up results for epacadostat in melanoma. Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab, Benjamin tells investors in a research note.
09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
MRK Merck
$62.66

-0.14 (-0.22%)

08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
OPK OPKO Health
$10.43

-0.31 (-2.89%)

10/07/16
JEFF
10/07/16
NO CHANGE
Target $10
JEFF
Hold
Palmetto no-coverage decision 'major setback' for OPKO, says Jefferies
Jefferies analyst Brandon Couillard views Palmetto's no-coverage decision yesterday for OPKO Health's 4Kscore prostate cancer test as a "major setback." Palmetto is a Medicare administrative contractor. The analyst views 4Kscore as a key near-term growth driver for OPKO and believes the company's local Medicare administrative contractor Novitas will likely follow suit. Without Medicare, 4K's commercial pathway from here is unclear, Couillard tells investors in a research note. He expects OPKO shares to trade lower on renewed reimbursement concerns. The analyst has a Hold rating on the name.
06/03/16
STPT
06/03/16
INITIATION
Target $16
STPT
Buy
OPKO Health initiated with a Buy at Standpoint Research
Target $16.
04/27/16
LTCO
04/27/16
NO CHANGE
Target $20
LTCO
Buy
OPKO Health resubmission of Rayaldee lifts overhang, says Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter believes OPKO Health resubmission of the New Drug Application for Rayaldee, which he notes came roughly within the timeframe he expected, lifts a potential overhang on the stock. The acceptance of the resubmission and issuance of a new PDUFA date suggest the issues identified by FDA at the third party supplier was limited and a suitable plan has been communicated, DeGeeter tells investors. The analyst keeps a Buy rating and $20 price target on OPKO shares.
03/31/16
JEFF
03/31/16
NO CHANGE
Target $11
JEFF
Hold
Uncertainty may persist after Opko's Health drug setback, says Jefferies
Jefferies analyst Brandon Couillard says the FDA's complete response letter to Opko's Health's New Drug Application for Rayaldee as a treatment for secondary hyperparathyroidism was a surprise. While nonfatal, the analyst believes the setback adds a new level of uncertainty around a key value driver that could weigh on the stock well into the second half of 2016. Couillard has a Hold rating and $11 price target on the shares.
RT Ruby Tuesday
$2.51

0.04 (1.62%)

02/18/16
SIDC
02/18/16
INITIATION
Target $6
SIDC
Neutral
Ruby Tuesday initiated with a Neutral at Sidoti
Target $6.
12/08/15
TIGR
12/08/15
DOWNGRADE
TIGR
Underperform
Ruby Tuesday downgraded to Underperform from Neutral at Tigress Financial
07/08/16
ADAM
07/08/16
NO CHANGE
ADAM
Casual dining checks point to significant deceleration in June, says Canaccord
Canaccord analyst Lynne Collier said the firm's checks indicate a material decline in sales and traffic trends in casual dining restaurants was seen in June. Among the reasons for the slowdown, Collier points to the reversal in gasoline prices, consumers eating at home and the uncertain political environment. The analyst projects same-store sales for the casual dining segment will decline 2%-2.5% in June. Publicly traded companies that own casual dining brands include Darden (DRI), Ruby Tuesday (RT), Bloomin' Brands (BLMN), DineEquity (DIN), Denny's (DENN), Brinker (EAT) and Buffalo Wild Wings (BWLD).
TSN Tyson Foods
$74.38

0.61 (0.83%)

06/07/16
JEFF
06/07/16
NO CHANGE
Target $70
JEFF
Buy
Jefferies recommends Tyson Foods following recent selloff
Jefferies analyst Akshay Jagdale attributes the recent selloff in protein stocks to the recent rally in grain prices and decline in pork margins. The analyst recommends buying shares of Tyson Foods (TSN) but continues to see "significant further potential downside" in Sanderson Farms (SAFM). Jagdale lowered his price target for Tyson to $70 and keeps a Buy rating on the name. He keeps a Hold rating on Hormel Foods (HRL) with a reduced price target of $34 and Underperform rating on Sanderson with a price target of $60.
07/26/16
CLVD
07/26/16
NO CHANGE
CLVD
Buy
Tyson Foods estimates raised further above consensus at Cleveland Research
Cleveland Research analyst Mike Piken raised Tyson Foods' FY16 and FY17 estimates further above consensus on improved chicken and beef outlook. The analyst is modeling Q3 earnings of $1.11, versus consensus of $1.05, driven by expectations for stronger beef EBIT margins, raised Q4 to $1.08, versus consensus of $1.06, to reflect a strong start for Pork, revised FY16 to $4.40, above consensus of $4.33, and FY17 to $4.79, versus consensus of $4.60. Piken rates Tyson a Buy.
09/19/16
SPHN
09/19/16
NO CHANGE
Target $85
SPHN
Overweight
Stephens makes Tyson Foods new Best Idea in Food and Agribusiness
Stephens analyst Farha Aslam is making Tyson Foods her firm's new Best Idea in Food and Agribusiness as she believes the company is well positioned for long-term growth. Consumers' growing interest in protein rich foods is creating opportunities to innovate new products, create brands in previously commodity categories, and improve margins, she added. Aslam reiterates an Overweight rating and $85 price target on the shares.
10/07/16
PIVT
10/07/16
DOWNGRADE
PIVT
Sell
Tyson Foods downgraded to Sell from Hold at Pivotal Research
Pivotal analyst Timothy Ramey downgraded Tyson Foods to Sell and slashed his price target to $40 from $100 due to the broiler price-fixing alleged in the class action complaint filed on September 2. Ramey said the complain alleges supply collusion occurred through nonpublic data exchange; detailed industry reports compiled on a daily or weekly basis by Agri Stats. Supposedly, the data has telling clues as to the identity of the other industry participants, making it is easy for the industry to collude on production cuts since they provide non-public information to Agri Stats on future production intentions. The analyst wondered why margins improved dramatically over the past seven years in a historically undisciplined industry. Ramey believes the class-action suit has merit and will lead to intense scrutiny of the broiler industry and questions the sustainability of chicken margins. He expects Tyson shares will be pressured until this complex issue is resolved and damages could be very substantial.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.